Novel Anti-Mesothelin Antibodies Enable Crystallography of the Intact Mesothelin Ectodo- main and Engineering of Potent, T cell-engaging Bispecific Therapeutics
Domain Annotation: SCOP2 Classification SCOP2 Database Homepage
| Chains | Type | Family Name | Domain Identifier | Family Identifier | Provenance Source (Version) |
|---|---|---|---|---|---|
| C [auth M] | SCOP2B Superfamily | Mesothelin-like | 8104137 | 3002829 | SCOP2B (2022-06-29) |
Domain Annotation: ECOD Classification ECOD Database Homepage
| Chains | Family Name | Domain Identifier | Architecture | Possible Homology | Homology | Topology | Family | Provenance Source (Version) |
|---|---|---|---|---|---|---|---|---|
| A [auth L] | e8cxcL1 | A: alpha arrays | X: cradle loop barrel | H: RIFT-related | T: FMN-binding split barrel | F: | ECOD (v295) | |
| B [auth H] | e8cxcH1 | A: alpha arrays | X: cradle loop barrel | H: RIFT-related | T: FMN-binding split barrel | F: | ECOD (v295) | |
| D [auth A] | e8cxcA1 | A: alpha arrays | X: cradle loop barrel | H: RIFT-related | T: FMN-binding split barrel | F: | ECOD (v295) |
SAbDab Antibody Annotation SAbDab Database Homepage
| Chain | Chain Class | Chain Subclass | Chain Type | Antigen Name(s) | Provenance Source |
|---|---|---|---|---|---|
| A [auth L] | Light Chain | IGKV1 | Kappa | mesothelin, cleaved form | SAbDab (2026-06-26) |
| B [auth H] | Heavy Chain | IGHV3 | - | mesothelin, cleaved form | SAbDab (2026-06-26) |
| D [auth A] | Light Chain | IGKV4 | Kappa | mesothelin, cleaved form | SAbDab (2026-06-26) |
Thera-SAbDab Antibody Annotation Thera-SAbDab Database Homepage
| Chain | Name | Target | Provenance Source |
|---|---|---|---|
| D [auth A] | Amatuximab | MSLN | Therapeutic SAbDab (2026-06-26) |
Gene Ontology: Gene Product Annotation Gene Ontology Database Homepage
InterPro: Protein Family Classification InterPro Database Homepage
| Chains | Accession | Name | Type |
|---|---|---|---|
| C [auth M] | IPR026664 | Stereocilin-related | Family |
| C [auth M] | IPR010335 | Mesothelin | Family |














